Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL), PT $19
March 3, 2025 11:47 AM ESTRaymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL)
The analyst comments "Monday before Market Open, Ocular Therapeutix reported 4Q24 results. Management hosted a call to discuss progress. The company reported $17.1M in total revenue vs. our estimated $17.8M and diluted EPS of $(0.29) vs. our projected $(0.26). Revenues... More
Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c
March 3, 2025 7:10 AM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.08 million versus the consensus estimate of $17.21 million.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... More